Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Kim

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Proteomic profiling in ovarian cancerGeoffrey Kim, Lucas Minig, Elise C Kohn
Journal of Proteomics|June 22, 2010
Proteomics and ovarian cancer: integrating proteomics information into clinical careJohn L Hays, Geoffrey Kim, Iulia Giuroiu, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 19, 2016
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder CancerJonathan Jarow, V Ellen Maher, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life CyclePasi A Jänne, Geoffrey Kim, Alice T Shaw, et al.
Cancer|October 20, 2011
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcomeGeoffrey Kim, Ben Davidson, Ryan Henning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted TherapiesJulia A Beaver, Abraham Tzou, Gideon M Blumenthal, et al.
Journal of Cellular and Molecular Medicine|February 16, 2012
L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancerMinshu Yu, Ryan Henning, Amanda Walker, et al.
The Oncologist|February 25, 2017
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker AnalysisJames Xunhai Xu, V Ellen Maher, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung CancerChana Weinstock, Sean Khozin, Daniel Suzman, et al.
Insights Into Imaging|August 26, 2024
CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapyYujia Xia, Jie Zhou, Xiaolei Xun, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Proteomic profiling in ovarian cancerGeoffrey Kim, Lucas Minig, Elise C Kohn
Journal of Proteomics|June 22, 2010
Proteomics and ovarian cancer: integrating proteomics information into clinical careJohn L Hays, Geoffrey Kim, Iulia Giuroiu, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 19, 2016
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder CancerJonathan Jarow, V Ellen Maher, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life CyclePasi A Jänne, Geoffrey Kim, Alice T Shaw, et al.
Cancer|October 20, 2011
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcomeGeoffrey Kim, Ben Davidson, Ryan Henning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted TherapiesJulia A Beaver, Abraham Tzou, Gideon M Blumenthal, et al.
Journal of Cellular and Molecular Medicine|February 16, 2012
L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancerMinshu Yu, Ryan Henning, Amanda Walker, et al.
The Oncologist|February 25, 2017
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker AnalysisJames Xunhai Xu, V Ellen Maher, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung CancerChana Weinstock, Sean Khozin, Daniel Suzman, et al.
Insights Into Imaging|August 26, 2024
CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapyYujia Xia, Jie Zhou, Xiaolei Xun, et al.
Pageof 3